Roche’s Columvi extends survival in Phase III DLBCL study
Roche has revealed promising outcomes from its Phase III STARGLO study, showcasing significant advancements in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) with Columvi (glofitamab). This study, conducted in collaboration with the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, demonstrates that Columvi, when combined with […]